Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Pembrolizumab Makes Inroads in Sarcoma Subtypes

TOP - November 2017, Vol 10, No 4 - Immunotherapy, Online First
Phoebe Starr

Chicago, IL—The tumor types amenable to immunotherapy with the PD-1 inhibitor pembrolizumab (Keytruda) keep expanding and now include sarcoma, which has been difficult to treat.

In the phase 2, multicenter clinical trial SARC028, pembrolizumab achieved encouraging responses in patients with soft-tissue sarcoma, especially in patients with undifferentiated pleomorphic sarcoma and liposarcoma, reported Melissa A. Burgess, MD, Assistant Professor of Medicine, Cancer Therapeutics Program, Hillman Cancer Center, University of Pittsburgh, Pennsylvania, at the 2017 ASCO annual meeting. Dr Burgess presented the final results and biomarker analysis from the clinical trial.

Response in undifferentiated pleomorphic sarcoma correlated with PD-L1 status and baseline infiltrating cytotoxic T-cells, she said.

“Pembrolizumab has clinical activity in undifferentiated pleomorphic sarcoma and liposarcoma, and expansion cohorts in these 2 subtypes are planned. Ongoing biomarker analysis may guide combination strategies,” said Dr Burgess.

SARC028: Phase 2 Clinical Trial

The SARC028 clinical trial evaluated single-agent pembrolizumab in 40 patients with advanced soft-tissue sarcomas (10 patients in each of the 4 different cohorts of undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, synovial sarcoma, and leiomyosarcoma) and in 40 patients with bone sarcomas (22 patients with osteosarcoma, 13 with Ewing sarcoma, and 5 with chondrosarcoma). The majority of the patients had received at least 2 previous therapies.

Pembrolizumab was administered at 200 mg intravenously every 3 weeks. Biopsies were obtained at baseline and during treatment. Tumors were tested for PD-L1 expression, and multicolor immunohistochemistry (IHC) was used to assess immune infiltrates.

At a median follow-up of 19 months, the projected overall response rate was 18%. In the soft-tissue sarcoma arm, there was 1 complete response and 6 partial responses: 1 complete response and 3 partial responses in patients with undifferentiated pleomorphic sarcoma, 2 partial responses in patients with liposarcoma, and 1 partial response in patients with synovial sarcoma. The median duration of response was 33 weeks. The median progression-free survival was 18 weeks, and the median overall survival was 49 weeks.

In the bone sarcoma arm, there were 2 partial responses, including 1 patient with osteosarcoma and 1 patient with chondrosarcoma. Overall, 9 patients had stable disease. The median duration of response was 43 weeks. The median progression-free survival was 8 weeks, and the median overall survival was 52 weeks.

“Serious adverse events were infrequent and not unexpected,” said Dr Burgess. Grade 3 or 4 adverse events were reported in 7% of patients in the soft-tissue sarcoma group and in 12% of patients in the bone sarcoma group.

Of the 70 biopsies that were analyzed for PD-L1 expression before treatment, 3 were positive (all in patients with undifferentiated pleomorphic sarcoma). Of these 3 biopsies, 2 were evaluable for response; there was 1 complete response and 1 partial response. None of the posttreatment biopsies were PD-L1–positive.

Multicolor IHC showed that patients who had responded to pembrolizumab had an increased number of infiltrating cytotoxic T-cells at baseline.

Dr Burgess and colleagues plan to conduct further biomarker analysis with IHC and phase 2 expansion cohort clinical trials in patients with undifferentiated pleomorphic sarcoma or liposarcoma.

Expert Commentary

Sarcoma is a complex type of cancer with many different subtypes. “There are multiple levels of complexity in attempting to understand immunotoxicity in sarcoma,” said formal discussant Jean-Yves Blay, MD, PhD, Centre Léon Bérard, Lyon, France.

“The authors are to be commended for looking at biomarkers with a multidimensional approach,” Dr Blay said. “Biomarkers could be a link to guide better therapy in the future,” he added.

“We can say that immunotherapy works in sarcoma, but it works in immune subsets of molecular subsets of histological subgroups. We must do better, and biomarkers are the key question,” concluded Dr Blay.

Related Items
FDA Grants Priority Review to Keytruda for Patients with High-Risk, Non–Muscle-Invasive Bladder Cancer
Web Exclusives published on December 3, 2019 in Bladder Cancer, FDA Updates, Immunotherapy
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC
Phoebe Starr
Web Exclusives published on November 25, 2019 in Lung Cancer
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC
Phoebe Starr
TOP - November 2019, Vol 12, No 4 published on November 7, 2019 in Lung Cancer
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives published on October 28, 2019 in ESMO, Breast Cancer
FDA Unveils Pilot Program to Expand Access to Investigational Oncology Drugs
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in ASCO
Studies Show ACA Reduces Disparities and Increases Access to Earlier Diagnosis and Treatment
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in ASCO
Reduced-Intensity Chemotherapy for Frail Elderly Patients with Advanced Gastroesophageal Cancer
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Geriatric Cancer
Enzalutamide or Apalutamide Added to ADT Are 2 New Options for Hormone-Sensitive Prostate Cancer
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Prostate Cancer
Practice-Changing Results: Olaparib Maintenance Therapy Extends Progression-Free Survival in Metastatic Pancreatic Cancer with BRCA Mutations
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Pancreatic Cancer
CAR T-Cell Therapy Targeting Solid Tumors
Chase Doyle
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Immunotherapy
Last modified: September 9, 2019